PMID- 20686378
OWN - NLM
STAT- MEDLINE
DCOM- 20101112
LR  - 20220330
IS  - 1525-1438 (Electronic)
IS  - 1048-891X (Linking)
VI  - 20
IP  - 4
DP  - 2010 May
TI  - Clinical significance of serum CA-125 and soluble tumor necrosis factor receptor 
      type I in cervical adenocarcinoma patients.
PG  - 588-92
LID - 10.1111/IGC.0b013e3181d5c27a [doi]
AB  - HYPOTHESIS: The purpose of this study was to answer the question whether the 
      measurement of the pretreatment tumor markers and cytokine levels would be of 
      clinical use in patients with cervical adenocarcinoma. METHODS: CA-125, 
      carcinoembryonic antigen (CEA), and squamous cell carcinoma (SCC), as well as 
      interleukin 6 (IL-6), IL-8, vascular endothelial growth factor, IL-1 receptor 
      antagonist, soluble tumor necrosis factor receptor type I (sTNF RI), and sTNF 
      RII, were assessed in the sera of 120 cervical adenocarcinoma patients. RESULTS: 
      CA-125 presented a better diagnostic sensitivity than did CEA and SCC, whereas 
      the concentration of most cytokines, except for sTNF RII, revealed higher 
      sensitivity, than did the standard tumor markers. The highest sensitivity was 
      found for sTNF RI. The concentrations of the examined parameters were found to be 
      significantly higher in patients with advanced stage (IIB-IV) as compared with 
      patients with I-IIA stage. [Float1]Serum concentration of IL-6 was the only one 
      that differs significantly, depending on the histological grade. During the 
      3-year follow-up, 25 patients relapsed, and 73 patients were disease-free. 
      Significantly higher pretreatment serum concentrations of the examined parameters 
      (except for SCC and IL-1 receptor antagonist) were found in patients who 
      developed recurrences. Soluble tumor necrosis factor receptor type I and CA-125 
      were found to present the highest sensitivity, with areas under the receiver 
      operating characteristic curve of 0.833 and 0.809, respectively. As the result of 
      univariate analysis, CA-125, CEA, sTNF RII, IL-6, sTNF RI, and clinical stage 
      were considered factors of poor prognosis. Multivariate analysis has proven that 
      CA-125 and clinical stage were the only significant independent prognostic 
      factors of the disease-free survival. CONCLUSION: CA-125 is an independent 
      prognostic factor for disease-free survival. Our results have also demonstrated 
      that sTNF RI is probably the most useful marker in cervical adenocarcinoma 
      patients, especially in the early stages of disease.
FAU - Kotowicz, Beata
AU  - Kotowicz B
AD  - Departments of Tumor Markers, Maria Sklodowska-Curie Cancer Center and Institute 
      of Oncology, Warsaw, Poland. bkotowicz@coi.pl
FAU - Kaminska, Janina
AU  - Kaminska J
FAU - Fuksiewicz, Malgorzata
AU  - Fuksiewicz M
FAU - Kowalska, Maria
AU  - Kowalska M
FAU - Jonska-Gmyrek, Joanna
AU  - Jonska-Gmyrek J
FAU - Gawrychowski, Krzysztof
AU  - Gawrychowski K
FAU - Sobotkowski, Janusz
AU  - Sobotkowski J
FAU - Skrzypczak, Maciej
AU  - Skrzypczak M
FAU - Starzewski, Jozef
AU  - Starzewski J
FAU - Bidzinski, Mariusz
AU  - Bidzinski M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int J Gynecol Cancer
JT  - International journal of gynecological cancer : official journal of the 
      International Gynecological Cancer Society
JID - 9111626
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CA-125 Antigen)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type I)
SB  - IM
MH  - Adenocarcinoma/*blood/pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*blood
MH  - CA-125 Antigen/*blood
MH  - Carcinoma, Squamous Cell/*blood/pathology
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*blood/pathology
MH  - Prognosis
MH  - Receptors, Tumor Necrosis Factor, Type I/*blood
MH  - Uterine Cervical Neoplasms/*blood/pathology
MH  - Young Adult
EDAT- 2010/08/06 06:00
MHDA- 2010/11/13 06:00
CRDT- 2010/08/06 06:00
PHST- 2010/08/06 06:00 [entrez]
PHST- 2010/08/06 06:00 [pubmed]
PHST- 2010/11/13 06:00 [medline]
AID - 00009577-201005000-00019 [pii]
AID - 10.1111/IGC.0b013e3181d5c27a [doi]
PST - ppublish
SO  - Int J Gynecol Cancer. 2010 May;20(4):588-92. doi: 10.1111/IGC.0b013e3181d5c27a.